By BY PAM BELLUCK, SHEILA KAPLAN AND REBECCA ROBBINS

Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen's Aduhelm, or aducanumab.

Published: July 19, 2021 at 10:12PM

from NYT Health https://ift.tt/2V2fsC8
via IFTTT


This free site is ad-supported. Learn more